As of 2024-12-12, the EV/EBITDA ratio of Reata Pharmaceuticals Inc (RETA) is -15.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RETA's latest enterprise value is 5,813.45 mil USD. RETA's TTM EBITDA according to its financial statements is -378.12 mil USD. Dividing these 2 quantities gives us the above RETA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 10.9x | 10.0x |
| Forward P/E multiples | 16.7x - 20.3x | 19.2x |
| Fair Price | (188.95) - (123.43) | (165.09) |
| Upside | -209.6% - -171.6% | -195.8% |
| Date | EV/EBITDA |